D-Serine and schizophrenia
What 3 graded rows on d-serine agree on for schizophrenia, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the D-Serine page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the D-Serine page, with its PubMed record.
Your question
D-Serine and schizophrenia
3 rows · 282 peopleSplit. 2 rows found an improvement and 1 found no difference.
- DGrade D× 2
- ∅No effect× 1
- Rows
- 3
- Trials
- 3
- People
- 282
Where they differ
From the rowsThe best-graded row, grade D, is a randomized trial of 45 people (2023) and found an improvement. 1 row is graded No effect, our grade for adequately powered trials that found no effect.
The row that found no difference was larger: 195 people, against a median of 44 people for the 2 rows that found an improvement.
The rows
2 improved · 1 no difference- DGrade DAuditory learning (pitch plasticity) during cognitive remediation in schizophrenia · Improved
RCT · n 45 · 2023 · Adults with schizophrenia or schizoaffective disorder on stable antipsychotics (USA)
80, 100 or 120 mg/kg once weekly with auditory training (12 D-serine and 3 placebo per dose cohort) · 3 weekly visits
Overall treatment effect on plasticity improvement (p = .014), largest at 80 and 100 mg/kg (d > 0.67); the within-group change at 120 mg/kg was not significant. Mismatch negativity was larger at 100 mg/kg than placebo (d = 1.0).
- DGrade DSymptoms and cognition at 30–120 mg/kg/day (schizophrenia, no placebo) · Improved
Open-label trial · n 42 · 2010 · Adults with schizophrenia or schizoaffective disorder stable on antipsychotics (USA)
30, 60 or 120 mg/kg/day · 4 weeks
Symptom and neuropsychological scores improved across doses, with larger cognitive gains at 60 mg/kg/day or more; there was no placebo group.
- ∅No effectNegative symptoms and cognition in schizophrenia (add-on to antipsychotics) · No difference
RCT · n 195 · 2012 · Adults with schizophrenia or schizoaffective disorder stable on antipsychotics, with persistent negative symptoms (multicenter)
2 g/day · 16 weeks
Both groups improved, with no significant difference between D-serine and placebo on negative symptoms (11.4% vs 14.8%) or MATRICS cognition (6.8% vs 6.1%). D-serine was well tolerated.